Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Onkologia w Praktyce Klinicznej - Edukacja
MENU
Na skróty Ahead of print Zdeponuj artykuł Nagroda imienia Profesora Krzysztofa Krzemienieckiego Zalecenia postępowania diagnostyczno-terapeutycznego

dostęp otwarty

Tom 8, Nr 1 (2022)
Wytyczne / stanowisko ekspertów
Opublikowany online: 2021-08-31
Pokaż PDF Pokaż HTML
Pobierz cytowanie

Nowotwory klatki piersiowej

Maciej Krzakowski1, Jacek Jassem2, Adam Antczak3, Katarzyna Błasińska4, Joanna Chorostowska-Wynimko5, Rafał Dziadziuszko2, Maciej Głogowski1, Tomasz Grodzki6, Dariusz Kowalski1, Rafał Krenke7, Renata Langfort8, Włodzimierz Olszewski9, Tadeusz Orłowski10, Paweł Śliwiński11, Andrzej Tysarowski12, Witold Rzyman13, Marek Woźniewski14
Onkol Prakt Klin Edu 2022;8(1):1-41.
Afiliacje
  1. Klinika Nowotworów Płuca i Klatki Piersiowej, Narodowy Instytut Onkologii — Państwowy Instytut Badawczy w Warszawie
  2. Katedra i Klinika Onkologii i Radioterapii, Gdański Uniwersytet Medyczny
  3. Klinika Pulmonologii Ogólnej i Onkologicznej, Uniwersytet Medyczny w Łodzi
  4. Zakład Radiologii, Instytut Gruźlicy i Chorób Płuc w Warszawie
  5. Zakład Genetyki i Immunologii Klinicznej, Instytut Gruźlicy i Chorób Płuc w Warszawie
  6. Oddział Kliniczny Chirurgii Klatki Piersiowej, Pomorska Akademia Medyczna w Szczecinie
  7. Katedra i Klinika Chorób Wewnętrznych, Pneumonologii i Alergologii, Warszawski Uniwersytet Medyczny
  8. Zakład Patomorfologii, Instytut Gruźlicy i Chorób Płuc w Warszawie
  9. Zakład Patomorfologii i Diagnostyki Laboratoryjnej, Narodowy Instytut Onkologii — Państwowy Instytut Badawczy w Warszawie
  10. Klinika Chirurgii, Instytut Gruźlicy i Chorób Płuc w Warszawie
  11. II Klinika Chorób Płuc, Instytut Gruźlicy i Chorób Płuc w Warszawie
  12. Pracownia Diagnostyki Genetycznej i Molekularnej Nowotworów, Narodowy Instytut Onkologii — Państwowy Instytut Badawczy w Warszawie
  13. Klinika Chirurgii Klatki Piersiowej, Gdański Uniwersytet Medyczny
  14. Wydział Fizjoterapii, Akademia Wychowania Fizycznego we Wrocławiu

dostęp otwarty

Tom 8, Nr 1 (2022)
WYTYCZNE POSTĘPOWANIA DIAGNOSTYCZNO-TERAPEUTYCZNEGO
Opublikowany online: 2021-08-31

Streszczenie

Brak

Streszczenie

Brak

Pełny tekst:

Pokaż PDF Pokaż HTML
Pobierz cytowanie

Słowa kluczowe

rak płuca; międzybłoniak opłucnej; nowotwory śródpiersia

Informacje o artykule
Tytuł

Nowotwory klatki piersiowej

Czasopismo

Onkologia w Praktyce Klinicznej - Edukacja

Numer

Tom 8, Nr 1 (2022)

Typ artykułu

Wytyczne / stanowisko ekspertów

Strony

1-41

Opublikowany online

2021-08-31

Wyświetlenia strony

3639

Wyświetlenia/pobrania artykułu

3400

Rekord bibliograficzny

Onkol Prakt Klin Edu 2022;8(1):1-41.

Słowa kluczowe

rak płuca
międzybłoniak opłucnej
nowotwory śródpiersia

Autorzy

Maciej Krzakowski
Jacek Jassem
Adam Antczak
Katarzyna Błasińska
Joanna Chorostowska-Wynimko
Rafał Dziadziuszko
Maciej Głogowski
Tomasz Grodzki
Dariusz Kowalski
Rafał Krenke
Renata Langfort
Włodzimierz Olszewski
Tadeusz Orłowski
Paweł Śliwiński
Andrzej Tysarowski
Witold Rzyman
Marek Woźniewski

Referencje (164)
  1. Wojciechowska U, Didkowska J, Michałek I i wsp. Nowotwory złośliwe w Polsce w 2018 roku. Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie – Państwowy Instytut Badawczy, Warszawa 2020. http://onkologia.org.pl/publikacje.
  2. https://ec.europa.eu/hea;th/tobacco/overview_en.
  3. Aberle DR, Adams AM, Berg CD, et al. National Lung Screening Trial Research Team. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5): 395–409.
    CrossRefPubMed
  4. Pedersen JH, Rzyman W, Veronesi G, et al. Recommendations from the European Society of Thoracic Surgeons (ESTS) regarding computed tomography screening for lung cancer in Europe. Eur J Cardiothorac Surg. 2017; 51(3): 411–420.
    CrossRefPubMed
  5. Oudkerk M, Devaraj A, Vliegenthart R, et al. European position statement on lung cancer screening. Lancet Oncol. 2017; 18(12): e754–e766.
    CrossRefPubMed
  6. Rzyman W, Didkowska J, Dziedzic R, et al. Consensus statement on a screening programme for the detection of early lung cancer in Poland. Adv Respir Med. 2018; 86(1): 53–74.
    CrossRefPubMed
  7. Jonas DE, Reuland DS, Reddy SM, et al. Screening for Lung Cancer With Low-Dose Computed Tomography: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021; 325(10): 971–987.
    CrossRefPubMed
  8. Koning Hde, Aalst Cv, Jong Pde, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial. N Engl J Med. 2020; 382(6): 503–513.
    CrossRef
  9. Jackman D, Johnson B. Small-cell lung cancer. Lancet. 2005; 366(9494): 1385–1396.
    CrossRef
  10. WHO Classification of Tumours Editorial Board. Thoracic Tumours, 5th Edition, Volume 5. 2021.
  11. Moreira A, Ocampo P, Xia Y, et al. A Grading System for Invasive Pulmonary Adenocarcinoma: A Proposal From the International Association for the Study of Lung Cancer Pathology Committee. J Thorac Oncol. 2020; 15(10): 1599–1610.
    CrossRef
  12. Lindeman NI, Cagle PT, Aisner DL, et al. Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. J Thorac Oncol. 2018; 13(3): 323–358.
    CrossRefPubMed
  13. Kelemkerian GP, Narula N, Kennedy EB, et al. Molecular testing guideline for the selection of patients with ling cancer for treatment with targeted tyrosine kinase inhibitors: American Society of Clinical Oncology Endorsement of the College of American Pathologists/International Association for the Study of Lung Cancer/Association for Molecular Pathology Clinical Practice Guideline Update. J Clin Oncol. 2018; 36: 911–919.
  14. Ettinger DS, Wood DE, Aisner D i wsp. NCCN Guidelines insights: non-small-cell lung cancer, version 2.2021. https://www.nccn.org/professionals/physician.gls/pdf.
  15. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl): e93S–e93e120S.
    CrossRefPubMed
  16. Callister ME, Baldwin DR, Akram AR, et al. members of the Guideline Development Group, Guideline Development Group, British Thoracic Society Pulmonary Nodule Guideline Development Group, British Thoracic Society Standards of Care Committee. British Thoracic Society guidelines for the investigation and management of pulmonary nodules. Thorax. 2015; 70 Suppl 2(8): ii1–ii54.
    CrossRefPubMed
  17. MacMahon H, Naidich DP, Goo JMo, et al. Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. Radiology. 2017; 284(1): 228–243.
    CrossRefPubMed
  18. Swensen SJ, Silverstein MD, Ilstrup DM, et al. The probability of malignancy in solitary pulmonary nodules. Application to small radiologically indeterminate nodules. Arch Intern Med. 1997; 157(8): 849–855.
    PubMed
  19. Swensen SJ, Silverstein MD, Edell ES, et al. Solitary pulmonary nodules: clinical prediction model versus physicians. Mayo Clin Proc. 1999; 74(4): 319–329.
    CrossRefPubMed
  20. McWilliams A, Tammemagi MC, Mayo JR, et al. Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med. 2013; 369(10): 910–919.
    CrossRefPubMed
  21. Herder GJ, van Tinteren H, Golding RP, et al. Clinical prediction model to characterize pulmonary nodules: validation and added value of 18F-fluorodeoxyglucose positron emission tomography. Chest. 2005; 128(4): 2490–2496.
    CrossRefPubMed
  22. De Leyn P, Dooms C, Kuzdzal J, et al. Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014; 45(5): 787–798.
    CrossRefPubMed
  23. Rivera M, Mehta A, Wahidi M. Establishing the Diagnosis of Lung Cancer. Chest. 2013; 143(5): 142–165.
    CrossRef
  24. Du Rand IA, Blaikley J, Booton R, et al. British Thoracic Society guideline for diagnostic flexible bronchoscopy in adults: accredited by NICE. Thorax. 2013; 68(Suppl 1): i1–i44.
    CrossRef
  25. Szlubowski A, Herth FJF, Soja J, et al. Endobronchial ultrasound-guided needle aspiration in non-small-cell lung cancer restaging verified by the transcervical bilateral extended mediastinal lymphadenectomy--a prospective study. Eur J Cardiothorac Surg. 2010; 37(5): 1180–1184.
    CrossRefPubMed
  26. Korevaar DA, Crombag LM, Cohen JF, et al. Added value of combined endobronchial and oesophageal endosonography for mediastinal nodal staging in lung cancer: a systematic review and meta-analysis. Lancet Respir Med. 2016; 4(12): 960–968.
    CrossRefPubMed
  27. Vilmann P, Clementsen PF, Colella S, et al. Combined endobronchial and esophageal endosonography for the diagnosis and staging of lung cancer: European Society of Gastrointestinal Endoscopy (ESGE) Guideline, in cooperation with the European Respiratory Society (ERS) and the European Society of Thoracic Surgeons (ESTS). Endoscopy. 2015; 47(6): 545–559.
    CrossRefPubMed
  28. Khan KA, Nardelli P, Jaeger A, et al. Navigational Bronchoscopy for Early Lung Cancer: A Road to Therapy. Adv Ther. 2016; 33(4): 580–596.
    CrossRefPubMed
  29. Labarca G, Folch E, Jantz M, et al. Adequacy of Samples Obtained by Endobronchial Ultrasound with Transbronchial Needle Aspiration for Molecular Analysis in Patients with Non-Small Cell Lung Cancer. Systematic Review and Meta-Analysis. Ann Am Thorac Soc. 2018; 15(10): 1205–1216.
    CrossRefPubMed
  30. Brierley JD, Gospodarowicz MK, Wittekind C. (red.). TNM Classification of malignant tumours (wyd 8). John Wiley and Sons Inc, Oksford 2016.
  31. Goldstraw P, Chansky K, Crowley J, et al. International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions, International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee Advisory Boards and Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016; 11(1): 39–51.
    CrossRefPubMed
  32. Brunelli A, Charloux A, Bolliger CT, et al. European Respiratory Society and European Society of Thoracic Surgeons joint task force on fitness for radical therapy. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (surgery and chemo-radiotherapy). Eur Respir J. 2009; 34(1): 17–41.
    CrossRefPubMed
  33. Fleisher L, Beckman J, Brown K, et al. ACC/AHA 2007 Guidelines on Perioperative Cardiovascular Evaluation and Care for Noncardiac Surgery. Circulation. 2007; 116(17): e418–e499.
    CrossRef
  34. Brunelli A, Kim AW, Berger KI, et al. Physiologic evaluation of the patient with lung cancer being considered for resectional surgery: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl): e166S–e190S.
    CrossRefPubMed
  35. Boujibar F, Gillibert A, Gravier FE, et al. Performance at stair-climbing test is associated with postoperative complications after lung resection: a systematic review and meta-analysis. Thorax. 2020; 75(9): 791–797.
    CrossRefPubMed
  36. Lim E, Baldwin D, Beckles M, et al. British Thoracic Society, Society for Cardiothoracic Surgery in Great Britain and Ireland. Guidelines on the radical management of patients with lung cancer. Thorax. 2010; 65 Suppl 3: iii1–ii27.
    CrossRefPubMed
  37. McElnay PJ, Choong A, Jordan E, et al. Outcome of surgery versus radiotherapy after induction treatment in patients with N2 disease: systematic review and meta-analysis of randomised trials. Thorax. 2015; 70(8): 764–768.
    CrossRefPubMed
  38. Rosen JE, Keshava HB, Yao X, et al. The Natural History of Operable Non-Small Cell Lung Cancer in the National Cancer Database. Ann Thorac Surg. 2016; 101(5): 1850–1855.
    CrossRefPubMed
  39. Rami-Porta R, Wittekind C, Goldstraw P, et al. International Association for the Study of Lung Cancer (IASLC) Staging Committee. Complete resection in lung cancer surgery: proposed definition. Lung Cancer. 2005; 49(1): 25–33.
    CrossRefPubMed
  40. Yan TD, Black D, Bannon PG, et al. Systematic review and meta-analysis of randomized and nonrandomized trials on safety and efficacy of video-assisted thoracic surgery lobectomy for early-stage non-small-cell lung cancer. J Clin Oncol. 2009; 27(15): 2553–2562.
    CrossRefPubMed
  41. Petrella F, Spaggiari L. The smaller the better: a new concept in thoracic surgery? Lancet Oncol. 2016; 17(6): 699–700.
    CrossRefPubMed
  42. Postmus PE, Kerr KM, Senan D, et al. Early-stage and locally-advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2017; 28(supl 4): iv1–iv21.
  43. Louie AV, Palma DA, Dahele M, et al. Management of early-stage non-small cell lung cancer using stereotactic ablative radiotherapy: controversies, insights, and changing horizons. Radiother Oncol. 2015; 114(2): 138–147.
    CrossRefPubMed
  44. Postoperative radiotherapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. PORT Meta-analysis Trialists Group. Lancet. 1998; 352(9124): 257–263.
    PubMed
  45. Le Péchoux C. Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data. Oncologist. 2011; 16(5): 672–681.
    CrossRefPubMed
  46. Billiet C, Decaluwé H, Peeters S, et al. Modern post-operative radiotherapy for stage III non-small cell lung cancer may improve local control and survival: a meta-analysis. Radiother Oncol. 2014; 110(1): 3–8.
    CrossRefPubMed
  47. Le Pe, Pourel N, Barlesi F, et al. LBA3 PR. An international randomized trial, comparing post-operative conformal radiotherapy (PORT) to no PORT, in patients with completely resected non-small-cell lung cancer and mediastinal N2 involvement: primary end-point analysis of LungART. Ann Oncol. 2020; 31(supl 4): LBA3.
  48. Pignon JP, Tribodet H, Scagliotti GV, et al. LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26(21): 3552–3559.
    CrossRefPubMed
  49. Wu YL, Tsuboi M, He J, et al. ADAURA Investigators. Osimertinib in Resected -Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020; 383(18): 1711–1723.
    CrossRefPubMed
  50. Cavalheri V, Burtin C, Formico VR, et al. Exercise training undertaken by people within 12 months of lung resection for non-small cell lung cancer. Cochrane Database Syst Rev. 2019; 6: CD009955.
    CrossRefPubMed
  51. Henshall CL, Allin L, Aveyard H. A Systematic Review and Narrative Synthesis to Explore the Effectiveness of Exercise-Based Interventions in Improving Fatigue, Dyspnea, and Depression in Lung Cancer Survivors. Cancer Nurs. 2019; 42(4): 295–306.
    CrossRefPubMed
  52. Lim E, Harris G, Patel A, et al. Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials. J Thorac Oncol. 2009; 4(11): 1380–1388.
    CrossRefPubMed
  53. Baas P, Belderbos JSA, van den Heuvel M. Chemoradiation therapy in nonsmall cell lung cancer. Curr Opin Oncol. 2011; 23(2): 140–149.
    CrossRefPubMed
  54. Li X, Li S, Yan S, et al. Impact of preoperative exercise therapy on surgical outcomes in lung cancer patients with or without COPD: a systematic review and meta-analysis. Cancer Manag Res. 2019; 11: 1765–1777.
    CrossRefPubMed
  55. Ni HJ, Pudasaini B, Yuan XT, et al. Exercise Training for Patients Pre- and Postsurgically Treated for Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis. Integr Cancer Ther. 2017; 16(1): 63–73.
    CrossRefPubMed
  56. Piraux E, Caty G, Reychler G. Effects of preoperative combined aerobic and resistance exercise training in cancer patients undergoing tumour resection surgery: A systematic review of randomised trials. Surg Oncol. 2018; 27(3): 584–594.
    CrossRefPubMed
  57. Eberhardt WEE, De Ruysscher D, Weder W, et al. Panel Members. 2nd ESMO Consensus Conference in Lung Cancer: locally advanced stage III non-small-cell lung cancer. Ann Oncol. 2015; 26(8): 1573–1588.
    CrossRefPubMed
  58. Aupérin A, Le Péchoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol. 2010; 28(13): 2181–2190.
    CrossRefPubMed
  59. Miller ED, Fisher JL, Haglund KE, et al. The Addition of Chemotherapy to Radiation Therapy Improves Survival in Elderly Patients with Stage III Non-Small Cell Lung Cancer. J Thorac Oncol. 2018; 13(3): 426–435.
    CrossRefPubMed
  60. Antonia SJ, Villegas A, Daniel D, et al. PACIFIC Investigators. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018; 379(24): 2342–2350.
    CrossRefPubMed
  61. Moeller B, Balagamwala EH, Chen A, et al. Palliative thoracic radiation therapy for non-small cell lung cancer: 2018 Update of an American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline. Pract Radiat Oncol. 2018; 8(4): 245–250.
    CrossRefPubMed
  62. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ. 1995; 311(7010): 899–909.
    CrossRefPubMed
  63. NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008; 26(28): 4617–4625.
    CrossRefPubMed
  64. Ardizzoni A, Boni L, Tiseo M, et al. CISCA (CISplatin versus CArboplatin) Meta-analysis Group. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007; 99(11): 847–857.
    CrossRefPubMed
  65. Pujol JL, Barlesi F, Daurès JP. Should chemotherapy combinations for advanced non-small cell lung cancer be platinum-based? A meta-analysis of phase III randomized trials. Lung Cancer. 2006; 51(3): 335–345.
    CrossRefPubMed
  66. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008; 26(21): 3543–3551.
    CrossRefPubMed
  67. Quoix E, Zalcman G, Oster JP, et al. Carboplatin and weekly paclitaxel doublet chemotherapy compared with monotherapy in elderly patients with advanced non-small-cell lung cancer: IFCT-0501 randomised, phase 3 trial. Lancet. 2011; 378(9796): 1079–1088.
    CrossRefPubMed
  68. Delbaldo C, Michiels S, Syz N, et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: a meta-analysis. JAMA. 2004; 292(4): 470–484.
    CrossRefPubMed
  69. Rossi A, Chiodini P, Sun JM, et al. Six versus fewer planned cycles of first-line platinum-based chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2014; 15(11): 1254–1262.
    CrossRefPubMed
  70. Paz-Ares L, Marinis Fde, Dediu M, et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial. Lancet Oncol. 2012; 13(3): 247–255.
    CrossRefPubMed
  71. Haaland B, Tan PS, de Castro G, et al. Meta-analysis of first-line therapies in advanced non-small-cell lung cancer harboring EGFR-activating mutations. J Thorac Oncol. 2014; 9(6): 805–811.
    CrossRefPubMed
  72. Haspinger ER, Agustoni F, Torri V, et al. Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. Crit Rev Oncol Hematol. 2015; 94(2): 213–227.
    CrossRefPubMed
  73. Yang JH, Wu YL, Schuler M, et al. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015; 16(2): 141–151.
    CrossRefPubMed
  74. Mok TS, Cheng Y, Zhou X, et al. Improvement in Overall Survival in a Randomized Study That Compared Dacomitinib With Gefitinib in Patients With Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. J Clin Oncol. 2018; 36(22): 2244–2250.
    CrossRefPubMed
  75. Soria JC, Ohe Y, Vansteenkiste J, et al. FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(2): 113–125.
    CrossRefPubMed
  76. Solomon BJ, Mok T, Kim DW, et al. PROFILE 1014 Investigators. First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med. 2014; 371(23): 2167–2177.
    CrossRefPubMed
  77. Soria JC, Tan DSW, Chiari R, et al. First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study. Lancet. 2017; 389(10072): 917–929.
    CrossRefPubMed
  78. Peters S, Camidge DR, Shaw AT, et al. ALEX Trial Investigators. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(9): 829–838.
    CrossRefPubMed
  79. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21): 2027–2039.
    CrossRefPubMed
  80. Shaw A, Bauer T, Marinis Fde, et al. First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer. N Engl J Med. 2020; 383(21): 2018–2029.
    CrossRef
  81. Shaw AT, Riely GJ, Bang YJ, et al. Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Ann Oncol. 2019; 30(7): 1121–1126.
    CrossRefPubMed
  82. Dziadziuszko R, Krebs MG, De Braud F, et al. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic Fusion-Positive Non-Small-Cell Lung Cancer. J Clin Oncol. 2021; 39(11): 1253–1263.
    CrossRefPubMed
  83. Ramalingam SS, Belani CP. Antiangiogenic agents in the treatment of nonsmall cell lung cancer: reality and hope. Curr Opin Oncol. 2010; 22(2): 79–85.
    CrossRefPubMed
  84. Rossi A. Cetuximab and non-small-cell lung cancer: end of the story? Lancet Oncol. 2013; 14(13): 1251–1253.
    CrossRefPubMed
  85. Reck M, Rodríguez-Abreu D, Robinson AG, et al. KEYNOTE-024 Investigators. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19): 1823–1833.
    CrossRefPubMed
  86. Carbone DP, Reck M, Paz-Ares L, et al. CheckMate 026 Investigators. First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 376(25): 2415–2426.
    CrossRefPubMed
  87. Sezer A, Kilickap S, Gümüş M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021; 397(10274): 592–604.
    CrossRef
  88. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. KEYNOTE-189 Investigators. Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 378(22): 2078–2092.
    CrossRefPubMed
  89. Paz-Ares L, Luft A, Vicente D, et al. Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21): 2040–2051.
    CrossRef
  90. Socinski MA, Jotte RM, Cappuzzo F, et al. IMpower150 Study Group. Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24): 2288–2301.
    CrossRefPubMed
  91. West H, McCleod M, Hussein M, et al. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019; 20(7): 924–937.
    CrossRefPubMed
  92. Jotte R, Cappuzzo F, Vynnychenko I, et al. Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial. J Thorac Oncol. 2020; 15(8): 1351–1360.
    CrossRefPubMed
  93. Paz-Ares L, Ciuleanu TE, Cobo M, et al. First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): an international, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(2): 198–211.
    CrossRefPubMed
  94. Mok TSK, Wu YL, Kudaba I, et al. KEYNOTE-042 Investigators. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019; 393(10183): 1819–1830.
    CrossRefPubMed
  95. Herbst RS, Giaccone G, de Marinis F, et al. Atezolizumab for First-Line Treatment of PD-L1-Selected Patients with NSCLC. N Engl J Med. 2020; 383(14): 1328–1339.
    CrossRefPubMed
  96. Haanen JB, Carbonnel F, Robert C, et al. ESMO Guidelines Committee. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017; 28(suppl_4): iv119–iv142.
    CrossRefPubMed
  97. Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018; 4(12): 1721–1728.
    CrossRefPubMed
  98. Hanna N, Shepherd F, Fossella F, et al. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy. J Clin Oncol. 2004; 22(9): 1589–1597.
    CrossRef
  99. Di Maio M, Chiodini P, Georgoulias V, et al. Meta-analysis of single-agent chemotherapy compared with combination chemotherapy as second-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2009; 27(11): 1836–1843.
    CrossRefPubMed
  100. Tan DSW, Yom SS, Tsao MS, et al. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol. 2016; 11(7): 946–963.
    CrossRefPubMed
  101. Mok TS, Wu YL, Ahn MJ, et al. AURA3 Investigators. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017; 376(7): 629–640.
    CrossRefPubMed
  102. Shaw AT, Kim DW, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013; 368(25): 2385–2394.
    CrossRefPubMed
  103. Camidge DR, Kim HR, Ahn MJ, et al. Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2018; 379(21): 2027–2039.
    CrossRefPubMed
  104. Shaw A, Kim T, Crinò L, et al. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial. The Lancet Oncology. 2017; 18(7): 874–886.
    CrossRef
  105. Novello S, Mazières J, Oh IJ, et al. Alectinib versus chemotherapy in crizotinib-pretreated anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer: results from the phase III ALUR study. Ann Oncol. 2018; 29(6): 1409–1416.
    CrossRefPubMed
  106. Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016; 17(7): 984–993.
    CrossRefPubMed
  107. Reck M, Kaiser R, Mellemgaard A, et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 2014; 15(2): 143–155.
    CrossRefPubMed
  108. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2): 123–135.
    CrossRefPubMed
  109. Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17): 1627–1639.
    CrossRefPubMed
  110. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017; 389(10066): 255–265.
    CrossRefPubMed
  111. Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016; 387(10027): 1540–1550.
    CrossRefPubMed
  112. Rosen LS, Gordon D, Tchekmedyian NS, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer. 2004; 100(12): 2613–2621.
    CrossRefPubMed
  113. Scagliotti GV, Hirsh V, Siena S, et al. Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol. 2012; 7(12): 1823–1829.
    CrossRefPubMed
  114. Guckenberger M, Lievens Y, Bouma A, et al. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation. Lancet Oncol. 2020; 21(1): e18–e28.
    CrossRef
  115. Kim C, Hoang CD, Kesarwala AH, et al. Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer. J Thorac Oncol. 2017; 12(2): 179–193.
    CrossRefPubMed
  116. Rossi A, Maio MDi, Chiodini P, et al. Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data. J Clin Oncol. 2012; 30(14): 1692–1698.
    CrossRef
  117. Sundstrøm S, Bremnes RM, Kaasa S, et al. Norwegian Lung Cancer Study Group. Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol. 2002; 20(24): 4665–4672.
    CrossRefPubMed
  118. Pujol JL, Carestia L, Daurès JP. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent. Br J Cancer. 2000; 83(1): 8–15.
    CrossRefPubMed
  119. Popat S, O'Brien M. Chemotherapy strategies in the treatment of small cell lung cancer. Anticancer Drugs. 2005; 16(4): 361–372.
    CrossRefPubMed
  120. Shao N, Jin S, Zhu W. An updated meta-analysis of randomized controlled trials comparing irinotecan/platinum with etoposide/platinum in patients with previously untreated extensive-stage small cell lung cancer. J Thorac Oncol. 2012; 7(2): 470–472.
    CrossRefPubMed
  121. Mansfield AS, Każarnowicz A, Karaseva N, et al. IMpower133 Study Group. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018; 379(23): 2220–2229.
    CrossRefPubMed
  122. Goldman JW, Dvorkin M, Chen Y, et al. CASPIAN investigators. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021; 22(1): 51–65.
    CrossRefPubMed
  123. Rudin CM, Awad MM, Navarro A, et al. KEYNOTE-604 Investigators. Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study. J Clin Oncol. 2020; 38(21): 2369–2379.
    CrossRefPubMed
  124. Fried DB, Morris DE, Poole C, et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol. 2004; 22(23): 4837–4845.
    CrossRefPubMed
  125. De Ruysscher D, Pijls-Johannesma M, Bentzen SM, et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol. 2006; 24(7): 1057–1063.
    CrossRefPubMed
  126. Faivre-Finn C, Snee M, Ashcroft L, et al. CONVERT Study Team. Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised, superiority trial. Lancet Oncol. 2017; 18(8): 1116–1125.
    CrossRefPubMed
  127. Slotman B, Tinteren Hv, Praag J, et al. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. Lancet. 2015; 385(9962): 36–42.
    CrossRef
  128. Slotman B, Faivre-Finn C, Kramer G, et al. EORTC Radiation Oncology Group and Lung Cancer Group. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007; 357(7): 664–672.
    CrossRefPubMed
  129. Slotman BJ, Mauer ME, Bottomley A, et al. Prophylactic cranial irradiation in extensive disease small-cell lung cancer: short-term health-related quality of life and patient reported symptoms: results of an international Phase III randomized controlled trial by the EORTC Radiation Oncology and Lung Cancer Groups. J Clin Oncol. 2009; 27(1): 78–84.
    CrossRefPubMed
  130. Takahashi T, Yamanaka T, Seto T, et al. Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2017; 18(5): 663–671.
    CrossRefPubMed
  131. Schneider BJ, Saxena A, Downey RJ. Surgery for early-stage small cell lung cancer. J Natl Compr Canc Netw. 2011; 9(10): 1132–1139.
    CrossRefPubMed
  132. Low M, Ben-Or S. Thoracic Surgery in Early-Stage Small Cell Lung Cancer. Thorac Surg Clin. 2018; 28(1): 9–14.
    CrossRefPubMed
  133. O'Brien MER, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006; 24(34): 5441–5447.
    CrossRefPubMed
  134. Jassem J. Tobacco smoking after diagnosis of cancer: clinical aspects. Transl Lung Cancer Res. 2019; 8(Suppl 1): S50–S58.
    CrossRefPubMed
  135. McMurry TL, Stukenborg GJ, Kessler LG, et al. More Frequent Surveillance Following Lung Cancer Resection Is Not Associated With Improved Survival: A Nationally Representative Cohort Study. Ann Surg. 2018; 268(4): 632–639.
    CrossRefPubMed
  136. Colt H, Murgu S, Korst R, et al. Follow-up and Surveillance of the Patient With Lung Cancer After Curative-Intent Therapy. Chest. 2013; 143(5): e437S–e454S.
    CrossRef
  137. Denis F, Lethrosne C, Pourel N, et al. Randomized Trial Comparing a Web-Mediated Follow-up With Routine Surveillance in Lung Cancer Patients. J Natl Cancer Inst. 2017; 109(9).
    CrossRefPubMed
  138. Baudin E, Caplin M, Garcia-Carbonero R, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org. Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021; 32(4): 439–451.
    CrossRefPubMed
  139. Nicholson AG, Sauter JL, Nowak AK, et al. EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. J Thorac Oncol. 2020; 15(1): 29–49.
    CrossRefPubMed
  140. Robinson B, Musk A, Lake R. Malignant mesothelioma. Lancet. 2005; 366(9483): 397–408.
    CrossRefPubMed
  141. Sinha S, Swift AJ, Kamil MA, et al. The role of imaging in malignant pleural mesothelioma: an update after the 2018 BTS guidelines. Clin Radiol. 2020; 75(6): 423–432.
    CrossRefPubMed
  142. Kindler HL, Ismaila N, Armato SG, et al. Treatment of Malignant Pleural Mesothelioma: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018; 36(13): 1343–1373.
    CrossRefPubMed
  143. Rice D, Rusch V, Pass H, et al. International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol. 2011; 6(8): 1304–1312.
    CrossRefPubMed
  144. Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008; 135(3): 620–6, 626.e1.
    CrossRefPubMed
  145. Rintoul R, Ritchie A, Edwards J, et al. Efficacy and cost of video-assisted thoracoscopic partial pleurectomy versus talc pleurodesis in patients with malignant pleural mesothelioma (MesoVATS): an open-label, randomised, controlled trial. Lancet. 2014; 384(9948): 1118–1127.
    CrossRefPubMed
  146. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol. 2003; 21(14): 2636–2644.
    CrossRefPubMed
  147. Muers MF, Stephens RJ, Fisher P, et al. MS01 Trial Management Group. Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial. Lancet. 2008; 371(9625): 1685–1694.
    CrossRefPubMed
  148. Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trial. Lancet. 2016; 387(10026): 1405–1414.
    CrossRefPubMed
  149. Grosso F, Steele N, Novello S, et al. Nintedanib Plus Pemetrexed/Cisplatin in Patients With Malignant Pleural Mesothelioma: Phase II Results From the Randomized, Placebo-Controlled LUME-Meso Trial. J Clin Oncol. 2017; 35(31): 3591–3600.
    CrossRefPubMed
  150. Nowak AK, Lesterhuis WJ, Kok PS, et al. Durvalumab with first-line chemotherapy in previously untreated malignant pleural mesothelioma (DREAM): a multicentre, single-arm, phase 2 trial with a safety run-in. Lancet Oncol. 2020; 21(9): 1213–1223.
    CrossRefPubMed
  151. Baas P, Scherpereel A, Nowak A, et al. First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial. Lancet. 2021; 397(10272): 375–386.
    CrossRef
  152. Cao C, Tian D, Manganas C, et al. Systematic review of trimodality therapy for patients with malignant pleural mesothelioma. Ann Cardiothorac Surg. 2012; 1(4): 428–437.
    CrossRefPubMed
  153. Evoli A, Lancaster E. Paraneoplastic disorders in thymoma patients. J Thorac Oncol. 2014; 9(9 Suppl 2): S143–S147.
    CrossRefPubMed
  154. Li HR, Gao J, Jin C, et al. Comparison between CT and MRI in the Diagnostic Accuracy of Thymic Masses. J Cancer. 2019; 10(14): 3208–3213.
    CrossRefPubMed
  155. Weis CA, Yao X, Deng Y, et al. Contributors to the ITMIG Retrospective Database. The impact of thymoma histotype on prognosis in a worldwide database. J Thorac Oncol. 2015; 10(2): 367–372.
    CrossRefPubMed
  156. Marx A, Ströbel P, Badve SS, et al. ITMIG consensus statement on the use of the WHO histological classification of thymoma and thymic carcinoma: refined definitions, histological criteria, and reporting. J Thorac Oncol. 2014; 9(5): 596–611.
    CrossRefPubMed
  157. Ruffini E, Fang W, Guerrera F, et al. Staging and Prognostic Factors Committee, Staging and Prognostic Factors-Thymic Domain Subcommittee, Staging and Prognostic Factors Subcommittees, Members of the Advisory Boards. The International Association for the Study of Lung Cancer Thymic Tumors Staging Project: The Impact of the Eighth Edition of the Union for International Cancer Control and American Joint Committee on Cancer TNM Stage Classification of Thymic Tumors. J Thorac Oncol. 2020; 15(3): 436–447.
    CrossRefPubMed
  158. Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer. 1981; 48(11): 2485–2492, doi: 10.1002/1097-0142(19811201)48:11<2485::aid-cncr2820481123>3.0.co;2-r.
    PubMed
  159. Falkson CB, Bezjak A, Darling G, et al. Lung Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care. The management of thymoma: a systematic review and practice guideline. J Thorac Oncol. 2009; 4(7): 911–919.
    CrossRefPubMed
  160. Patel S, Macdonald OK, Nagda S, et al. Evaluation of the role of radiation therapy in the management of malignant thymoma. Int J Radiat Oncol Biol Phys. 2012; 82(5): 1797–1801.
    CrossRefPubMed
  161. Kashima J, Okuma Y, Murata H, et al. Chemoradiotherapy for unresectable cases of thymic epithelial tumors: a retrospective study. J Thorac Dis. 2017; 9(10): 3911–3918.
    CrossRefPubMed
  162. Girard N. Chemotherapy and targeted agents for thymic malignancies. Expert Rev Anticancer Ther. 2012; 12(5): 685–695.
    CrossRefPubMed
  163. Bokemeyer C, Nichols CR, Droz JP, et al. Extragonadal germ cell tumors of the mediastinum and retroperitoneum: results from an international analysis. J Clin Oncol. 2002; 20(7): 1864–1873.
    CrossRefPubMed
  164. den Bakker MA, Marx A, Mukai K, et al. Mesenchymal tumours of the mediastinum--part I. Virchows Arch. 2015; 467(5): 487–500.
    CrossRefPubMed

Regulamin

Ważne: serwis https://journals.viamedica.pl/ wykorzystuje pliki cookies. Więcej >>

Używamy informacji zapisanych za pomocą plików cookies m.in. w celach statystycznych, dostosowania serwisu do potrzeb użytkownika (np. język interfejsu) i do obsługi logowania użytkowników. W ustawieniach przeglądarki internetowej można zmienić opcje dotyczące cookies. Korzystanie z serwisu bez zmiany ustawień dotyczących cookies oznacza, że będą one zapisane w pamięci komputera. Więcej informacji można znaleźć w naszej Polityce prywatności.

Czym są i do czego służą pliki cookie możesz dowiedzieć się na stronie wszystkoociasteczkach.pl.

 

Wydawcą serwisu jest  VM Media Group sp. z o.o., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl